In an effort to build its immuno-oncology franchise, Takeda Pharmaceutical has entered into a strategic collaboration with Turnstone Biologicsto develop products from Turnstone’s proprietary vaccinia virus platform targeting a broad range of cancer indications. As part of the US$1 B deal, the two companies will also co-develop and co-commercialise Turnstone’s lead programme, RIVAL-01.